A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs
Latest Information Update: 23 Oct 2021
At a glance
- Drugs ORYN 1001 (Primary) ; Azathioprine; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Oryn Therapeutics
- 15 Oct 2021 Status changed from recruiting to completed.
- 26 Mar 2021 Planned End Date changed from 1 Apr 2021 to 1 Sep 2021.
- 26 Mar 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Sep 2021.